Latest news with #NurExoneBiologicInc
The Market Online
21-05-2025
- Business
- The Market Online
Developing new therapies for traumatic central nervous system injuries
NurExone Biologic Inc. , an innovative biotech company pioneering exosome based therapies designed to help patients recover from traumatic central nerve system injuries. There's a lot happening at NurExone from the formation of a US subsidiary and a new CEO to lead that subsidiary to their plans for uplisting to a major US exchange and recent funding activity. Lyndsay Malchuk recently caught up with CEO, Shaltiel to an inside scoop on some exciting preclinical results and an upcoming scientific report that can mark a major step in the research development. The following is a transcription of the above video, and The Market Online has edited it for clarity . Lyndsay: I think the best place to actually start is with that US subsidiary. So tell us maybe a little bit about Exo-Top and can you tell us about the new Exo-Top CEO? Lior: Yes. So let's start with the context. We bought just recently in the end of last year, huge assets, which is the master cell bank in the US, a former US company. And these assets will stay in the US and this is the reason that we open the subsidiary there. The aim of the subsidiary is first of all to hold the master cell bank, develop it to a working cell bank and produce naive exosomes, which is the first step of our therapy for NurExone's supply, NurExone Ltd for further research and development for clinical phase. And because we are sitting on large assets, also offer exosomes in the highest standards as a B2B business for cosmetic, aesthetic and other vendors that would like to purchase it. Regarding the CEO, I'm very glad to have Jacob Licht on our Board. He came with more than 25 years of experience in a large pharmaceutical, including a lot of experience in operations and M&A. I think that bring NurExone to a new level. Speaking American and not just entrepreneurship Israelis. Lyndsay: Let's peel back just a little bit more here if we can. Now you've engaged with a number of North American investment banks in order to achieve that US exchange listing. So my question is, what can you share about that process, where it stands and what it means for NurExone's next phase of growth? Lior: Sure. So, we completed in April a $2.3 million Canadian dollar raise. We are well funded with the back wind of a very successful JP Morgan event in San Francisco. We got a lot of the attention from US and Canadian investment banks. And our plan is now to up list NurExone from Canada to a major stock exchange in the US in order to be in the right market. Because as you know, the majority of large pharmaceuticals that got into a clinic need to be on a major stock exchange with the support of the market and the liquidity. And we will get the support from these investment banks to raise in two steps pre IPO raise and after that a full IPO to a major stock exchange in the US. Lyndsay: How do you plan to use the funds to work and are you looking at any additional support from the government for grants in Israel? Lior: Yes, we are looking all the time non-governmental funds. We have interest from the Israeli defense ministry in order to apply NurExone products in the battlefield. I believe that it'll also be relevant for the US DOD, (Department of Defense). So non-governmental is of course one of the sources to support NurExone. But on top of that, as I said, we would like to use the raise now and the raise that we completed in April in order to proceed into a clinical stage company and provide all the necessary IND enabling study in order to submit it to the FDA. Lyndsay: I'm going to flip over here to go over some preclinical information that's exciting as well. So, the latest preclinical results around the ExoPTEN look really promising when it comes to improving motor function. So for you, what stood out in the findings? I mean, how does this move the needle for your research? Lior: That's a very good point. We changed models at NurExone, moving from a very, very severe and not physiological model, which is full transection the spinal cord, which we could see a motor sensoric and bladder functional recovery. But now we move to a more physiological in order to get more physiological data in a compression model, meaning that you're pressing the nerves and not cutting it. That's more of a fit to what happens to a human when you have an injury. And we see even stronger recovery. Okay. If you take a scale, the scale of motor recovery is even higher when you use the therapy. So this gives us a lot of hope that we are in the right direction. On top of that, we have also the results that we are getting more and more rats into the optic nerve damage showing the same strong recovery after just 18 days in an ERG. I think we are on the right track. We need to make sure that we have the whole package that the necessary for the FDA in order to translate our company to a clinical stage company. Lyndsay: Let's lean into that research further. I know that there's a scientific report that's coming out soon as well. So how big of a moment is that for you and what kind of response are you hoping for from regulators or investors or even potential partners? Lior: The correspondence with the FDA is critical. So one of the things that we want to keep is the dialogue. The last one that we had is in the end of 2023 when we completed the pre-IND. Since then we had a lot of progress. Our research became even more advanced, the production that we do in the 3D bioreactors is getting more advanced. So we have more questions today to the FDA and when sharing that we are getting ourself more focus, what is the right track? So, keeping the dialogue is critical and we are working with the regulator to help us bring the therapy further into a clinical stage. NurExone Biologic's website is and you can find them on the Venture Exchange under the ticker symbol NRX. Join the discussion: Find out what everybody's saying about this stock on the NurExone Biologic investor discussion forum, and check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here
Associated Press
10-03-2025
- Business
- Associated Press
NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - March 10, 2025) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company') is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange ('TSXV'). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone's leadership in the emerging field of exosome-based therapies and regenerative medicine for central nervous system injuries. This recognition also highlights NurExone's strong market performance and strategic advances in the past year including 110% share price appreciation and 209% market cap growth. The TSX Venture 50™ recognizes the top 50 performing issuers out of the 1,605 i listed issuers on the TSXV, across all sectors. Each company recognized is evaluated and chosen based on a combination of metrics including one year share price appreciation and market capitalization growth. In 2024, the 50 selected companies delivered an impressive average share price appreciation of 207% ii demonstrating strong investor confidence in high-growth enterprises. 'We are deeply honored to be recognized as a TSX Venture 50™ company. This reflects our unwavering commitment to advancing exosome-based therapies and creating long-term value for our shareholders,' said Dr. Lior Shaltiel, CEO of NurExone. 'It's a testament to the growing investor confidence in our mission to revolutionize regenerative medicine, the strength of our scientific breakthroughs, and the dedication of our talented team.' Key milestones driving NurExone's success include significant progress in the development of ExoPTEN, the Company's proprietary exosome therapy for acute spinal cord injuries, as well as NurExone's establishment of its U.S. subsidiary, Exo-Top Inc., which accelerates its exosome production capabilities and advancement of their clinical pipeline. These efforts will help position NurExone as a leader in the rapidly growing field of exosome-based therapies. The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024, 80% of the TSXV Venture 50™ companies operated internationally across Europe, South America, Africa, and beyond iii, further highlighting the global impact of TSXV-listed firms. Yoram Drucker, Chairman of NurExone, added 'being recognized by the TSX Venture 50™ is a significant milestone for NurExone, highlighting our strong financial performance and growth trajectory. We look forward to continuing our success as we expand our presence in the U.S. and explore new listing opportunities.' About NurExone NurExone Biologic Inc. is a TSXV, OTCQB and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets [iv]. Regulatory milestones, including Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: [email protected] Oak Hill Financial Inc. 2 Bloor Street, Suite 2900 Toronto, Ontario M4W 3E2 Investor Relations - Canada Phone: +1-647-479-5803 Email: [email protected] Dr. Eva Reuter Investor Relations - Germany Phone: +49-69-1532-5857 Allele Capital Partners Investor Relations - U.S. Phone: +1 978-857-5075 FORWARD-LOOKING STATEMENTS This press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company's advancing exosome-based therapies and creating long term value for shareholders; growing investor confidence in the Company's mission; Exo-Top Inc. accelerating its exosome production capabilities and advancing its clinical pipeline; the Company becoming a leader in the field of exosome-based therapies; the continued success of the Company; the Company expanding its presence in the U.S. and exploring new listing opportunities; the Company completing clinical trials in the U.S. and Europe; the Company's future plans and expectations; growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone advancing its development pipeline; NurExone's focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology offering solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company will advance exosome-based therapies and create long term value for shareholders; there being growing investor confidence in the Company's mission; Exo-Top Inc. will accelerate its exosome production capabilities and advance its clinical pipeline; the Company will become a leader in the field of exosome-based therapies; the Company will continue to succeed; the Company will expand its presence in the U.S. and explore new listing opportunities; the Company will complete clinical trials in the U.S. and Europe; there will be growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone will advance its development pipeline; NurExone will continue to focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology will offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel, and on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; the Company's inability to expand into further studies; Exo-Top not have the intended benefits on the Company and/or its business; the Company be unable to advance exosome-based therapies and/or create long term value for shareholders; investor confidence in the Company's mission deteriorating; the Company not becoming a leader in the field of exosome-based therapies; the Company being unable to expand its presence in the U.S. and/or explore new listing opportunities; the Company being unable to initiate and/or complete clinical trials in the U.S. and Europe; clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas deteriorating; NurExone being unable to advance its development pipeline; NurExone being unable to focus on developing regenerative exosome-based therapies for central nervous system injuries; the NurExone platform technology being unable to offer solutions to companies interested in quality exosomes and/or minimally invasive targeted delivery systems for other indications; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's annual information form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
